Company: ENTXW
Filing Date: 2025-05-30
Form Type: S-3
Source: 0001178913-25-002025
Chunk: 43

Company: Entera Bio Ltd.
Filing Date: 2025-05-30
Form: S-3
Chunk 43
---
 if any, will be your sole source of gain; |

| • | Our reliance on third parties to conduct our clinical trials and on third-party suppliers to supply or produce our product candidates; |

| • | Our interpretation of FDA feedback and guidance and how such guidance may impact our clinical development plan; |

| • | Our ability to use and expand our drug delivery technology (“N-Tab™”) to additional product candidates; |

| • | Our operation as a development stage company with limited operating history and a history of operating losses and our ability to fund our operations going forward; |

| • | Our competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories we pursue; |

| • | Our ability to establish and maintain development and commercialization collaborations; |

| • | Our ability to manufacture and supply enough material to support our clinical trials and any potential future commercial requirements; |

| • | The size of any market we may target and the adoption of our product candidates, if approved, by physicians and patients; |

| • | Our ability to obtain, maintain and protect our intellectual property and operate our business without infringing, misappropriating, or otherwise violating any intellectual property rights of others; |

| • | Our ability to retain key personnel and recruit additional qualified personnel; |

| • | Our ability to comply with laws and regulations that currently apply or become applicable to our business; |

| • | our ability to manage growth; and |

| • | The duration and intensity of the ongoing Israel-Hamas War, and escalation of Hezbollah's conflict since October 2023 as well as the developing conflict with Iran and its proxies in the Middle East, such as the Houthis in Yemen and 
 militias in Iraq and Syria, and their impact on our operations and workforce.                                                                                                                                                           |

All forward-looking statements contained in this prospectus are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We caution investors not to rely heavily on the forward-looking statements we make or that are made on our behalf. Except as required by applicable law, we are under no duty, and expressly disclaim any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in any annual, quarterly or current reports that we may file with the SEC